Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Peter M. Glazer, MD, PhD

Robert E. Hunter Professor of Therapeutic Radiology and Professor of Genetics; Chair, Therapeutic Radiology

Contact Information

Peter M. Glazer, MD, PhD

Office Location

Mailing Address

  • Therapeutic Radiology

    PO Box 208040

    New Haven, CT 06520-8040

    United States

Glazer Lab

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Tumor hypoxia, DNA repair, and cancer therapy: Our work established that hypoxia is a key driver of genetic instability in solid tumors. We have shown that tumor hypoxia causes down-regulation of specific DNA repair genes, particularly the homology-dependent repair factors, BRCA1 and RAD51. This down-regulation of DNA repair in hypoxic cancer cells renders them vulnerable to therapeutic strategies that exploit the specific repair deficiencies, providing the basis for novel, rationally designed cancer therapies. We also discovered that the anti-angiogenic agent, cediranib, not only damages tumors by interrupting their blood supply and thereby inducing hypoxia but also down-regulates DNA repair (Kaplan, Science Translational Medicine), sensitizing cancer cells to PARP inhibitors and highlighting a therapeutic strategy that is currently being pursued in clinical trials.

Oncometabolites and DNA repair. In collaborative work with the Bindra lab published in Science Translational Medicine, Nature Genetics, and Nature, we found that elevated levels of the metabolites, 2-hydroxyglutarate, fumarate, and succinate, generated in human malignancies by neomorphic IDH mutations or by inherited mutations in the fumarate hydratase or succinate dehydrogenase genes, also suppress DNA repair via dysregulation of chromatin signaling and induce PARP inhibitor sensitivity, providing a new approach to treat these cancers that is being tested in current clinical trials.

DNA repair inhibitors for cancer therapy. We have made the unexpected finding that a cell-penetrating lupus autoantibody, 3E10, has potential as a targeted therapy for DNA-repair deficient malignancies (Hansen, Science Translational Medicine 2012). We found that 3E10 is synthetically lethal to BRCA2- or PTEN-deficient human cancer cells and sensitizes such cells to radiation and doxorubicin. Mechanistically we found that the 3E10 antibody binds to and inhibits the DNA repair factor, RAD51 (Turchick, NAR, 2019), providing a basis for its effects.

Tumor specific targeting of microRNAs and other undruggable targets. We have examined microRNA regulation of DNA repair, identifying several key microRNAs that mediate the stress response to hypoxia and to radiation. This work led to a collaborative effort to target peptide nucleic acids (PNAs) to tumors in mice using pH sensitive peptides as a means to inhibit oncogenic microRNA pathways (Cheng, Nature, 2015). We recently applied this approach to deliver antisense PNAs to inhibit the otherwise undruggable DNA repair factor, Ku80, to sensitize tumors to radiation (Kaplan, Molecular Cancer Research, 2020).

Gene editing via triple helix formation: From an interest in studying cellular DNA repair and recombination pathways, we recognized the utility of DNA triple helix formation as a mechanism for the site-specific induction of gene editing in human cells. We are focusing on triplex forming peptide nucleic acids (PNAs), delivered via polymer nanoparticles, as tools to mediate targeted modification of human disease-related genes. In collaborative work with the Saltzman, Egan, Gallagher, and Kumar labs, we have been optimizing this approach for application in human hematopoietic stem cells and in mouse models of human genetic diseases (Bahal, Nature Communications 2016, Ricciardi, Nature Communications 2018).

Extensive Research Description

Novel pathways that regulate the DNA damage response. Recently, in collaborative work with the Bindra lab, we discovered that the oncometabolite, 2-hydroxyglutarate, generated by neomorphic IDH mutations in gliomas and other maligancies suppresses homologous recombination and confers PARP inhibitor sensitivity, identifying a new approach to treat these malignancies (Sulkowski, Science Translational Medicine, 2017). Similarly, we found that elevated level of the Krebs cycle intermediates, fumarate and succinate, associated with the hereditary cancer syndromes, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and Succinate Dehydrogenase-related Hereditary Paraganglioma and Pheochromocytoma (SDH PGL/PCC), also suppress the homologous recombination pathway, rendering these tumors vulnerable to synthetic lethal targeting with PARP inhibitors, pointing to a new therapeutic approach for advanced HLRCC and SDH PGL/PCC, both incurable when metastatic (Sulkowski, Nature Genetics, 2018). The use of PARP inhibitors in these malignancies is currently being tested in several clinical trials directly based on our work. Mechanistically, we determined that oncometabolites suppress homology dependent repair (HDR) by inhibiting the histone lysine demethylase, KDM4B. This causes aberrant hypermethylation of H3K9 across the genome and thereby disrupts the normal temporal and spatial pattern of HDR factor recruitment to sites of DNA DSBs (Sulkowski, Nature, 2020). We also recently characterized a novel pathway by which mitochondrial DNA damage mediates signaling to upregulate nuclear DNA repair (Wu, Nature Metabolism, 2019).

Novel approaches to cancer therapy. Effective cancer treatment depends on achieving a therapeutic window in which there is greater toxicity to the malignant cells than to normal, healthy tissue. We have sought to exploit synthetic lethality by seeking agents that are more toxic to cancer cells deficient in homology-dependent DNA repair. This applies to cancers with genetic defects in genes such as BRCA1, BRCA2, PALB2, and PTEN. But it also applies to hypoxic cancer cells in which there is down-regulation of the HDR genes, BRCA1 and RAD51. Our efforts in this area have focused on a novel lupus-derived, cell-penetrating antibody that functions as a DNA repair inhibitor to radiosensitize cells (Hansen, Science Translational Medicine 2012) and a promising class of natural products (Colis, Nature Chemistry 2014). We have also sought to exploit the acidic tumor microenvironment using a novel pH-dependent trans-membrane delivery peptide (pHLIP) to introduce anti-microRNA peptide nucleic acids (PNAs) antisense agents to disrupt oncomiR addiction (Cheng, Nature 2015). We recently applied this approach to deliver antisense PNAs to inhibit the otherwise undruggable DNA repair factor, Ku80, to sensitize tumors to radiation (Kaplan, Molecular Cancer Research, 2020). Recently, we have shown that the anti-angiogenic agent, cediranib, not only damages tumors by interrupting their blood supply and thereby inducing hypoxia but also directly down-regulates DNA repair, sensitizing cancer cells to PARP inhibitors and suggesting a strategy for targeted treatment that is currently being pursued in several clinical trials at Yale and elsewhere (Kaplan, Science Translational Medicine, 2019).

Hypoxia causes genetic instability, down-regulates DNA repair, and promotes gene silencing. In the mid 1990's, we developed the hypothesis that the hypoxic tumor microenvironment could be a cause of genetic instability in cancer. This was contrary to the dogma at the time, because it was thought that under hypoxia there would be less oxidative damage to DNA. We showed that growth of cancer cells in vivo in tumor xenografts produces an elevated mutation rate compared to growth of the same cells in culture (Reynolds, Cancer Res. 1996), and we went on to demonstrate that this effect could be attributed to hypoxia. Since then, we have systematically dissected the mechanisms underlying this effect. These mechanisms include transcriptional downregulation of the homology-dependent repair genes RAD51 and BRCA1 (Bindra, Cancer Res. 2006), of the Fanconi pathway gene FANCD2(Scanlon, Molecular Cancer Res. 2014) and of the mismatch repair gene, MLH1 (Mihaylova, Mol. Cell. Biol. 2003) plus induction of microRNAs 210 and 373 that suppress expression of several DNA repair factors (Crosby, Cancer Res. 2009). In addition, besides acute transcriptional downregulation, our laboratory discovered that hypoxia promotes silencing of the DNA repair genes, BRCA1 and MLH1, in a pathway that is dependent on the histone lysine demethylase, LSD-1 (Lu, Mol. Cell. Biol. 2011 and Lu, Cell Reports 2014).

Triplex DNA provokes DNA repair, and triplex-forming oligonucleotides can stimulate site-specific gene editing in vivo. In the early 1990's, triplex-forming oligonucleotides (TFOs) were being touted as tools to suppress gene expression by binding to promoter sites to block transcription factor access. However, I realized that the site-specific binding properties of TFOs could also be used to mediate sequence-specific gene editing. We discovered that triplex formation, itself, constitutes a helical alteration sufficient to induce DNA repair at the site of the triplex (Wang, Science 1996 and Vasquez, Science 2000), via the nucleotide excision repair (NER) pathway. This activates the target site for recombination with "donor DNAs" via homology-dependent repair. After a systematic evaluation of DNA analogs for improved triple helix formation in cells, we have focused on peptide nucleic acids (PNAs), which have a neutral polyamide backbone and bind DNA with high affinity. Using PNAs, we demonstrated successful editing of the beta-globin gene in human primary hematopoietic stem cells. In collaboration with the Saltzman lab, we developed a strategy to encapsulate the PNAs and donor DNAs in polymer-based, biocompatible nanoparticles to achieve effective in vivo delivery in mice with minimal toxicity. Recent work with the Egan lab has demonstrated the ability of nanoparticles containing PNAs and donor DNAs to mediate editing of the F508del CFTR gene mutation in airway epithelia in vivo in a mouse model of cystic fibrosis (McNeer, Nature Communications 2015) and to mediate substantial correction of anemia and in mice with thalassemia by simple intravenous injection of PNA and DNA containing nanoparticles in adult mice (Bahal, Nature Communications 2016) and in fetal mice via in utero injection (Ricciardi, Nature Communications, 2018).

Coauthors

Research Interests

DNA Repair; Genetics; Radiation; Gene Targeting; Radiation Oncology; Recombinational DNA Repair; Gene Editing

Research Image

DNA repair

Selected Publications

  • Response to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effectTakahashi T, Stoiljkovic M, Song E, Gao X, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu Z, Kristant A, Zhang Y, Sulkowski P, Glazer P, Kaczmarek L, Horvath T, Iwasaki A. Response to: Elevated L1 expression in ataxia telangiectasia likely explained by an RNA-seq batch effect Neuron 2023, 111: 612-613. PMID: 36863323, DOI: 10.1016/j.neuron.2023.02.006.
  • Nanoparticle‐mediated genome editing in single‐cell embryos via peptide nucleic acidsPutman R, Ricciardi A, Carufe K, Quijano E, Bahal R, Glazer P, Saltzman W. Nanoparticle‐mediated genome editing in single‐cell embryos via peptide nucleic acids Bioengineering & Translational Medicine 2022 DOI: 10.1002/btm2.10458.
  • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal Of Clinical Oncology 2022, jco2102947. PMID: 36256912, DOI: 10.1200/jco.21.02947.
  • In vivo correction of cystic fibrosis mediated by PNA nanoparticlesPiotrowski-Daspit AS, Barone C, Lin CY, Deng Y, Wu D, Binns TC, Xu E, Ricciardi AS, Putman R, Garrison A, Nguyen R, Gupta A, Fan R, Glazer PM, Saltzman WM, Egan ME. In vivo correction of cystic fibrosis mediated by PNA nanoparticles Science Advances 2022, 8: eabo0522. PMID: 36197984, PMCID: PMC9534507, DOI: 10.1126/sciadv.abo0522.
  • Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomideSingh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide Pediatric Blood & Cancer 2022, e30020. PMID: 36151992, DOI: 10.1002/pbc.30020.
  • LINE-1 activation in the cerebellum drives ataxiaTakahashi T, Stoiljkovic M, Song E, Gao XB, Yasumoto Y, Kudo E, Carvalho F, Kong Y, Park A, Shanabrough M, Szigeti-Buck K, Liu ZW, Kristant A, Zhang Y, Sulkowski P, Glazer PM, Kaczmarek LK, Horvath TL, Iwasaki A. LINE-1 activation in the cerebellum drives ataxia Neuron 2022, 110: 3278-3287.e8. PMID: 36070749, PMCID: PMC9588660, DOI: 10.1016/j.neuron.2022.08.011.
  • An ELISA-based platform for rapid identification of structure-dependent nucleic acid–protein interactions detects novel DNA triplex interactorsEconomos NG, Thapar U, Balasubramanian N, Karras GI, Glazer PM. An ELISA-based platform for rapid identification of structure-dependent nucleic acid–protein interactions detects novel DNA triplex interactors Journal Of Biological Chemistry 2022, 298: 102398. PMID: 35988651, PMCID: PMC9493393, DOI: 10.1016/j.jbc.2022.102398.
  • Abstract 663: Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibodyQuijano E, Saucedo D, Khang M, Liu Y, Ludwig D, Turner B, Squinto S, Bindra R, Saltzman W, Escobar-Hoyos L, Glazer P. Abstract 663: Systemic targeting of therapeutic RNA to cancer via a novel, cell-penetrating and nucleic acid binding, monoclonal antibody Cancer Research 2022, 82: 663-663. DOI: 10.1158/1538-7445.am2022-663.
  • Antispacer peptide nucleic acids for sequence-specific CRISPR-Cas9 modulationEconomos NG, Quijano E, Carufe KEW, Perera JDR, Glazer PM. Antispacer peptide nucleic acids for sequence-specific CRISPR-Cas9 modulation Nucleic Acids Research 2022, 50: e59-e59. PMID: 35235944, PMCID: PMC9177974, DOI: 10.1093/nar/gkac095.
  • Chapter 11 Oncometabolites, epigenetic marks, and DNA repairDow J, Glazer P. Chapter 11 Oncometabolites, epigenetic marks, and DNA repair 2022, 191-202. DOI: 10.1016/b978-0-323-91081-1.00008-x.
  • Vulnerability of IDH1 mutant cancers to histone deacetylase inhibition via orthogonal suppression of DNA repairDow J, Krysztofiak A, Liu Y, Colon-Rios DA, Rogers FA, Glazer PM. Vulnerability of IDH1 mutant cancers to histone deacetylase inhibition via orthogonal suppression of DNA repair Molecular Cancer Research 2021, 19: molcanres.mcr-21-0456-e.2021. PMID: 34535560, PMCID: PMC8642278, DOI: 10.1158/1541-7786.mcr-21-0456.
  • Abstract P135: Systemic targeting of a CNS tumor (medulloblastoma) using a novel cell-penetrating, nucleic acid binding, monoclonal antibodyQuijano E, Khang M, Turner B, Squinto S, Bindra R, Saltzman W, Glazer P. Abstract P135: Systemic targeting of a CNS tumor (medulloblastoma) using a novel cell-penetrating, nucleic acid binding, monoclonal antibody Molecular Cancer Therapeutics 2021, 20: p135-p135. DOI: 10.1158/1535-7163.targ-21-p135.
  • Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune MachineryHayman TJ, Glazer PM. Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune Machinery International Journal Of Molecular Sciences 2021, 22: 12761. PMID: 34884568, PMCID: PMC8657976, DOI: 10.3390/ijms222312761.
  • 582: In vivo nanoparticle-mediated therapeutic nucleic acid delivery for CF treatmentPiotrowski-Daspit A, Bracaglia L, Barone C, Nguyen R, Glazer P, Egan M, Saltzman W. 582: In vivo nanoparticle-mediated therapeutic nucleic acid delivery for CF treatment Journal Of Cystic Fibrosis 2021, 20: s277. DOI: 10.1016/s1569-1993(21)02005-1.
  • Correction to ‘Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity’Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM. Correction to ‘Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity’ NAR Cancer 2021, 3: zcab047-. PMID: 34888524, PMCID: PMC8651162, DOI: 10.1093/narcan/zcab047.
  • Abstract LB169: Systemic Administration of an antibody/RNA complex results in tumor specific delivery of immunostimulatory RNAs and tumor growth suppression in a mouse model of melanomaQuijano E, Liu Y, Squinto S, Turner B, Glazer P. Abstract LB169: Systemic Administration of an antibody/RNA complex results in tumor specific delivery of immunostimulatory RNAs and tumor growth suppression in a mouse model of melanoma Cancer Research 2021, 81: lb169-lb169. DOI: 10.1158/1538-7445.am2021-lb169.
  • Peptide nucleic acids and their role in gene regulation and editingPerera JDR, Carufe KEW, Glazer PM. Peptide nucleic acids and their role in gene regulation and editing Biopolymers 2021, 112: e23460. PMID: 34129732, DOI: 10.1002/bip.23460.
  • BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancerRaimundo L, Paterna A, Calheiros J, Ribeiro J, Cardoso DSP, Piga I, Neto SJ, Hegan D, Glazer PM, Indraccolo S, Mulhovo S, Costa JL, Ferreira M, Saraiva L. BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancer British Journal Of Pharmacology 2021, 178: 3627-3647. PMID: 33899955, PMCID: PMC9124438, DOI: 10.1111/bph.15506.
  • Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA MutationKim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.
  • Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicityGayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM. Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity NAR Cancer 2021, 3: zcab021-. PMID: 34316708, PMCID: PMC8210154, DOI: 10.1093/narcan/zcab021.
  • The NIH Somatic Cell Genome Editing programSaha K, Sontheimer EJ, Brooks PJ, Dwinell MR, Gersbach CA, Liu DR, Murray SA, Tsai SQ, Wilson RC, Anderson DG, Asokan A, Banfield JF, Bankiewicz KS, Bao G, Bulte JWM, Bursac N, Campbell JM, Carlson DF, Chaikof EL, Chen ZY, Cheng RH, Clark KJ, Curiel DT, Dahlman JE, Deverman BE, Dickinson ME, Doudna JA, Ekker SC, Emborg ME, Feng G, Freedman BS, Gamm DM, Gao G, Ghiran IC, Glazer PM, Gong S, Heaney JD, Hennebold JD, Hinson JT, Khvorova A, Kiani S, Lagor WR, Lam KS, Leong KW, Levine JE, Lewis JA, Lutz CM, Ly DH, Maragh S, McCray PB, McDevitt TC, Mirochnitchenko O, Morizane R, Murthy N, Prather RS, Ronald JA, Roy S, Roy S, Sabbisetti V, Saltzman WM, Santangelo PJ, Segal DJ, Shimoyama M, Skala MC, Tarantal AF, Tilton JC, Truskey GA, Vandsburger M, Watts JK, Wells KD, Wolfe SA, Xu Q, Xue W, Yi G, Zhou J. The NIH Somatic Cell Genome Editing program Nature 2021, 592: 195-204. PMID: 33828315, PMCID: PMC8026397, DOI: 10.1038/s41586-021-03191-1.
  • Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistanceDong YL, Vadla GP, Lu J, Ahmad V, Klein TJ, Liu LF, Glazer PM, Xu T, Chabu CY. Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance Communications Biology 2021, 4: 374. PMID: 33742110, PMCID: PMC7979758, DOI: 10.1038/s42003-021-01898-5.
  • Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive PeptidesDharmaratne NU, Kaplan AR, Glazer PM. Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides Cells 2021, 10: 541. PMID: 33806273, PMCID: PMC8000199, DOI: 10.3390/cells10030541.
  • Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal SarcomasEder JP, Doroshow DB, T. K, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, DOI: 10.1200/po.20.00247.
  • Nanoparticles for delivery of agents to fetal lungsUllrich SJ, Freedman-Weiss M, Ahle S, Mandl HK, Piotrowski-Daspit AS, Roberts K, Yung N, Maassel N, Bauer-Pisani T, Ricciardi AS, Egan ME, Glazer PM, Saltzman WM, Stitelman DH. Nanoparticles for delivery of agents to fetal lungs Acta Biomaterialia 2021, 123: 346-353. PMID: 33484911, PMCID: PMC7962939, DOI: 10.1016/j.actbio.2021.01.024.
  • Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK PathwayLu Y, Liu Y, Oeck S, Zhang GJ, Schramm A, Glazer PM. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway Cancer Research 2020, 80: 4655-4667. PMID: 32873635, PMCID: PMC7642024, DOI: 10.1158/0008-5472.can-20-1192.
  • Abstract 6242: Development of alphalex™-toxin low pH targeting conjugates for the treatment of solid tumorsGayle S, Aiello R, Bechtold J, Bourassa P, Csengery J, Deshpande K, Jones K, Lopresti-Morrow L, Maguire R, Marshall D, Moore H, Paradis T, Tylaska L, Zhang Q, Volkmann R, Bindra R, Glazer P, Paralkar V. Abstract 6242: Development of alphalex™-toxin low pH targeting conjugates for the treatment of solid tumors Cancer Research 2020, 80: 6242-6242. DOI: 10.1158/1538-7445.am2020-6242.
  • Abstract 6249: CBX-12: A low pH targeting alphalex™-exatecan conjugate for the treatment of solid tumorsAiello R, Gayle S, Bechtold J, Bourassa P, Csengery J, Deshpande K, Jones K, Lopresti-Morrow L, Maguire R, Marshall D, Moore H, Paradis T, Tylaska L, Zhang Q, Volkmann R, Bindra R, Glazer P, Paralkar V. Abstract 6249: CBX-12: A low pH targeting alphalex™-exatecan conjugate for the treatment of solid tumors Cancer Research 2020, 80: 6249-6249. DOI: 10.1158/1538-7445.am2020-6249.
  • Abstract 1877: Hypoxia induces EGFR inhibitor resistance in lung cancer cells by upregulation of fibroblast growth factor receptor 1 (FGFR1) via MAPK pathwayLu Y, Liu Y, Oeck S, Zhang G, Glazer P. Abstract 1877: Hypoxia induces EGFR inhibitor resistance in lung cancer cells by upregulation of fibroblast growth factor receptor 1 (FGFR1) via MAPK pathway Cancer Research 2020, 80: 1877-1877. DOI: 10.1158/1538-7445.am2020-1877.
  • Oncometabolites suppress DNA repair by disrupting local chromatin signallingSulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, Noronha K, Bao X, Li J, Shuch BM, King MC, Bindra RS, Glazer PM. Oncometabolites suppress DNA repair by disrupting local chromatin signalling Nature 2020, 582: 586-591. PMID: 32494005, PMCID: PMC7319896, DOI: 10.1038/s41586-020-2363-0.
  • Ku80-Targeted pH-Sensitive Peptide–PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing RadiationKaplan AR, Pham H, Liu Y, Oyaghire S, Bahal R, Engelman DM, Glazer PM. Ku80-Targeted pH-Sensitive Peptide–PNA Conjugates Are Tumor Selective and Sensitize Cancer Cells to Ionizing Radiation Molecular Cancer Research 2020, 18: 873-882. PMID: 32098827, PMCID: PMC7272299, DOI: 10.1158/1541-7786.mcr-19-0661.
  • Mitochondrial DNA stress signalling protects the nuclear genomeWu Z, Oeck S, West AP, Mangalhara KC, Sainz AG, Newman LE, Zhang XO, Wu L, Yan Q, Bosenberg M, Liu Y, Sulkowski PL, Tripple V, Kaech SM, Glazer PM, Shadel GS. Mitochondrial DNA stress signalling protects the nuclear genome Nature Metabolism 2019, 1: 1209-1218. PMID: 32395698, PMCID: PMC7213273, DOI: 10.1038/s42255-019-0150-8.
  • Impact of hypoxia on DNA repair and genome integrity.Kaplan AR, Glazer PM. Impact of hypoxia on DNA repair and genome integrity. Mutagenesis 2019, 35: 61-68. PMID: 31282537, PMCID: PMC7317153, DOI: 10.1093/mutage/gez019.
  • Abstract SY21-02: Oncometabolites suppress homologous recombination DNA repair by inhibition of chromatin remodeling at the DNA double-strand breakSulkowski P, Oeck S, Li J, Shuch B, King M, Bindra R, Glazer P. Abstract SY21-02: Oncometabolites suppress homologous recombination DNA repair by inhibition of chromatin remodeling at the DNA double-strand break 2019, sy21-02-sy21-02. DOI: 10.1158/1538-7445.sabcs18-sy21-02.
  • Abstract SY21-02: Oncometabolites suppress homologous recombination DNA repair by inhibition of chromatin remodeling at the DNA double-strand breakSulkowski P, Oeck S, Li J, Shuch B, King M, Bindra R, Glazer P. Abstract SY21-02: Oncometabolites suppress homologous recombination DNA repair by inhibition of chromatin remodeling at the DNA double-strand break Cancer Research 2019, 79: sy21-02-sy21-02. DOI: 10.1158/1538-7445.am2019-sy21-02.
  • Abstract 2981: Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitorParalkar V, Aiello R, Marshall D, Csengery J, Bourassa P, Zhang Q, Robinson B, Lopresti-Morrow L, Bechtold J, Tylaska L, Paradis T, Slaybaugh G, Visca H, Moshnikova A, Weerakkody D, Andreev O, Reshetnyak Y, Engelman D, Bindra R, Glazer P, Hellsund P. Abstract 2981: Targeting solid tumor acidic microenvironment with an alphalex PARP inhibitor Cancer Research 2019, 79: 2981-2981. DOI: 10.1158/1538-7445.am2019-2981.
  • Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.Bindra R, Sundaram R, Aiello R, Marshall D, Bourassa P, Csengery J, Zhang Q, Robinson B, lopresti-Morrow L, Bechtold J, Tylaska L, Paradis T, Paralkar V, Hellsund P, Glazer P. Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform. Journal Of Clinical Oncology 2019, 37: e14664-e14664. DOI: 10.1200/jco.2019.37.15_suppl.e14664.
  • Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51 Science Translational Medicine 2019, 11 PMID: 31092693, PMCID: PMC6626544, DOI: 10.1126/scitranslmed.aav4508.
  • Debugging the genetic code: non-viral in vivo delivery of therapeutic genome editing technologiesPiotrowski-Daspit AS, Glazer P, Saltzman WM. Debugging the genetic code: non-viral in vivo delivery of therapeutic genome editing technologies Current Opinion In Biomedical Engineering 2018, 7: 24-32. PMID: 30984891, PMCID: PMC6456264, DOI: 10.1016/j.cobme.2018.08.002.
  • PTEN Regulates Non-Homologous End Joining by Epigenetic Induction of NHEJ1/XLFSulkowski PL, Scanlon SE, Oeck S, Glazer PM. PTEN Regulates Non-Homologous End Joining by Epigenetic Induction of NHEJ1/XLF Molecular Cancer Research 2018, 16: molcanres.0581.2017. PMID: 29739874, PMCID: PMC6072556, DOI: 10.1158/1541-7786.mcr-17-0581.
  • Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repairSulkowski PL, Sundaram RK, Oeck S, Corso CD, Liu Y, Noorbakhsh S, Niger M, Boeke M, Ueno D, Kalathil AN, Bao X, Li J, Shuch B, Bindra RS, Glazer PM. Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair Nature Genetics 2018, 50: 1086-1092. PMID: 30013182, PMCID: PMC6072579, DOI: 10.1038/s41588-018-0170-4.
  • In utero nanoparticle delivery for site-specific genome editingRicciardi AS, Bahal R, Farrelly JS, Quijano E, Bianchi AH, Luks VL, Putman R, López-Giráldez F, Coşkun S, Song E, Liu Y, Hsieh WC, Ly DH, Stitelman DH, Glazer PM, Saltzman WM. In utero nanoparticle delivery for site-specific genome editing Nature Communications 2018, 9: 2481. PMID: 29946143, PMCID: PMC6018676, DOI: 10.1038/s41467-018-04894-2.
  • Production of 2-Hydroxyglutarate by IDH Mutant Malignancies Induces a BRCAness State That Can be Exploited By PARP Inhibitors and RadiationCorso C, Bindra R, Glazer P, Sulkowski P, Robinson N, Scanlon S, Purshouse K, Bai H, Liu Y, Sundaram R, Hegan D, Fons N, Breuer G, Song Y, Mishra-Gorur K, De Feyter H, de Graaf R, Surovtseva Y, Kachman M, Halene S, Gunel M. Production of 2-Hydroxyglutarate by IDH Mutant Malignancies Induces a BRCAness State That Can be Exploited By PARP Inhibitors and Radiation International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e68. DOI: 10.1016/j.ijrobp.2017.06.754.
  • A cell-penetrating antibody inhibits human RAD51 via direct bindingTurchick A, Hegan DC, Jensen RB, Glazer PM. A cell-penetrating antibody inhibits human RAD51 via direct binding Nucleic Acids Research 2017, 45: gkx871-. PMID: 29036688, PMCID: PMC5714174, DOI: 10.1093/nar/gkx871.
  • Abstract LB-290: Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitorsSulkowski P, Corso C, Robinson N, Scanlon S, Purshouse K, Bai H, Liu Y, Sundaram R, Hegan D, Fons N, Breuer G, Song Y, Mishra K, Feyter H, Graaf R, Surovtseva Y, Kachman M, Halene S, Gunel M, Glazer P, Bindra R. Abstract LB-290: Oncometabolites induce a BRCAness state that can be exploited by PARP inhibitors Cancer Research 2017, 77: lb-290-lb-290. DOI: 10.1158/1538-7445.am2017-lb-290.
  • Abstract 2480: Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL -deficient human renal cell carcinomaScanlon S, Sulkowski P, Glazer P. Abstract 2480: Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL -deficient human renal cell carcinoma Cancer Research 2017, 77: 2480-2480. DOI: 10.1158/1538-7445.am2017-2480.
  • Abstract 2482: Inhibition of RAD51 with a cell penetrating antibody, 3E10Glazer P, Turchick A. Abstract 2482: Inhibition of RAD51 with a cell penetrating antibody, 3E10 Cancer Research 2017, 77: 2482-2482. DOI: 10.1158/1538-7445.am2017-2482.
  • Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors.Bindra R, Sulkowski P, Corso C, Glazer P, Shuch B. Induction of a BRCAness state by oncometabolites and exploitation by PARP inhibitors. Journal Of Clinical Oncology 2017, 35: 11586-11586. DOI: 10.1200/jco.2017.35.15_suppl.11586.
  • Abstract B25: “TargetDBR”—A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate DNA repair targeted drug discoveryHollick J, Abriola L, Bono F, Hegan D, Klingbeil P, Liu Y, Sundaram R, Surovtseva Y, Whittaker M, Bindra R, Glazer P. Abstract B25: “TargetDBR”—A DNA repair drug and target discovery collaboration: Exploiting synthetic lethal, high content, and functional cellular reporter assays to accelerate DNA repair targeted drug discovery Molecular Cancer Research 2017, 15: b25-b25. DOI: 10.1158/1557-3125.dnarepair16-b25.
  • 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivitySulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity Science Translational Medicine 2017, 9 PMID: 28148839, PMCID: PMC5435119, DOI: 10.1126/scitranslmed.aal2463.
  • Regulation of DNA Repair by HypoxiaLu Y, Glazer P. Regulation of DNA Repair by Hypoxia 2016, 169-188. DOI: 10.1142/9789813147324_0007.
  • In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle deliveryBahal R, Ali McNeer N, Quijano E, Liu Y, Sulkowski P, Turchick A, Lu YC, Bhunia DC, Manna A, Greiner DL, Brehm MA, Cheng CJ, López-Giráldez F, Ricciardi A, Beloor J, Krause DS, Kumar P, Gallagher PG, Braddock DT, Mark Saltzman W, Ly DH, Glazer PM. In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery Nature Communications 2016, 7: 13304. PMID: 27782131, PMCID: PMC5095181, DOI: 10.1038/ncomms13304.
  • Chemically Modified Gamma PNAs Targeting microRNA-210 as a Novel Anticancer Therapy With Specificity for Hypoxic Solid TumorsGlazer P, Gupta A, Liu Y, Quijano E, Saltzman W. Chemically Modified Gamma PNAs Targeting microRNA-210 as a Novel Anticancer Therapy With Specificity for Hypoxic Solid Tumors International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e597. DOI: 10.1016/j.ijrobp.2016.06.2125.
  • Abstract 1075: Chemically modified gamma PNAs targeting oncomiR-210 as a potential anticancer therapyGupta A, Liu Y, Quijano E, Saltzman W, Glazer P. Abstract 1075: Chemically modified gamma PNAs targeting oncomiR-210 as a potential anticancer therapy Cancer Research 2016, 76: 1075-1075. DOI: 10.1158/1538-7445.am2016-1075.
  • Abstract 2748: Targeting DNA repair deficient cancers with the cell-penetrating autoantibody 3E10Turchick A, Glazer P. Abstract 2748: Targeting DNA repair deficient cancers with the cell-penetrating autoantibody 3E10 Cancer Research 2016, 76: 2748-2748. DOI: 10.1158/1538-7445.am2016-2748.
  • Abstract LB-029: Negative transcriptional and epigenetic regulation of DNA repair pathways by the heavy metals nickel and arsenicScanlon S, Scanlon C, Hegan D, Sulkowski P, Glazer P. Abstract LB-029: Negative transcriptional and epigenetic regulation of DNA repair pathways by the heavy metals nickel and arsenic Cancer Research 2016, 76: lb-029-lb-029. DOI: 10.1158/1538-7445.am2016-lb-029.
  • Precise Genome Modification Using Triplex Forming Oligonucleotides and Peptide Nucleic AcidsBahal R, Gupta A, Glazer P. Precise Genome Modification Using Triplex Forming Oligonucleotides and Peptide Nucleic Acids 2016, 93-110. DOI: 10.1007/978-1-4939-3509-3_6.
  • E2F8 and its target genes as novel therapeutic targets for lung cancerPark S, Lee J, Platt J, Sweasy J, Glazer P, Herbst R, Koo J. E2F8 and its target genes as novel therapeutic targets for lung cancer Journal Of Thoracic Oncology 2016, 11: s29. DOI: 10.1016/j.jtho.2015.12.048.
  • Genomic predictors of biochemical failure following radical prostatectomy.Aneja S, Yu J, Glazer P. Genomic predictors of biochemical failure following radical prostatectomy. Journal Of Clinical Oncology 2016, 34: 114-114. DOI: 10.1200/jco.2016.34.2_suppl.114.
  • mRNA Expression of TP53 Attenuates Survival of HPV+ Locally Advanced Head and Neck CancerAneja S, Contessa J, Husain Z, Glazer P, Hansen J, Bindra R, Yu J. mRNA Expression of TP53 Attenuates Survival of HPV+ Locally Advanced Head and Neck Cancer International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e350-e351. DOI: 10.1016/j.ijrobp.2015.07.1440.
  • Genomic Predictors of Biochemical Failure Following Radical ProstatectomyAneja S, Gross C, Glazer P, Yu J. Genomic Predictors of Biochemical Failure Following Radical Prostatectomy International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e251-e252. DOI: 10.1016/j.ijrobp.2015.07.1180.
  • Abstract 2887: Epigenetic silencing of the DNA repair genes, BRCA1 and MLH1, induced by hypoxic stress in a pathway dependent on the histone demethylase, LSD1Lu Y, Chu A, Wajapeyee N, Turker M, Glazer P. Abstract 2887: Epigenetic silencing of the DNA repair genes, BRCA1 and MLH1, induced by hypoxic stress in a pathway dependent on the histone demethylase, LSD1 2015, 2887-2887. DOI: 10.1158/1538-7445.am2015-2887.
  • Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epitheliumMcNeer NA, Anandalingam K, Fields RJ, Caputo C, Kopic S, Gupta A, Quijano E, Polikoff L, Kong Y, Bahal R, Geibel JP, Glazer PM, Saltzman WM, Egan ME. Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium Nature Communications 2015, 6: 6952. PMID: 25914116, PMCID: PMC4480796, DOI: 10.1038/ncomms7952.
  • pHLIP® Targeting and Delivery of PNA to Silence MicroRNA in Tumor Cells§Engelman D, Cheng C, Bahal R, Babar I, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock D, Glazer P, Saltzman W, Slack F. pHLIP® Targeting and Delivery of PNA to Silence MicroRNA in Tumor Cells§ Biophysical Journal 2015, 108: 552a. DOI: 10.1016/j.bpj.2014.11.3029.
  • MicroRNA silencing for cancer therapy targeted to the tumour microenvironmentCheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment Nature 2014, 518: 107-110. PMID: 25409146, PMCID: PMC4367962, DOI: 10.1038/nature13905.
  • Abstract 977: Characterizing the regulation and function of miR-155 in hypoxia biologyCzochor J, Glazer P. Abstract 977: Characterizing the regulation and function of miR-155 in hypoxia biology 2014, 977-977. DOI: 10.1158/1538-7445.am2014-977.
  • Imaging and Treating Tumors by Targeting their Acidity with Phlip, a Ph-Sensitve Insertion PeptideEngelman D, An M, Andreev O, Barrera F, Bahal R, Bosenberg M, Cheng C, Glazer P, Karabadzhak A, Reshetnyak Y, Saltzman W, Slack F, Svoronos A, Thevenin D. Imaging and Treating Tumors by Targeting their Acidity with Phlip, a Ph-Sensitve Insertion Peptide Biophysical Journal 2014, 106: 231a. DOI: 10.1016/j.bpj.2013.11.1350.
  • Abstract 4319: Lupus antibody-based cancer therapy.Hansen J, Chan G, Liu Y, Hegan D, Dalal S, Dray E, Kwon Y, Xu Y, Xu X, Peterson-Roth E, Geiger E, Liu Y, Gera J, Sweasy J, Sung P, Rockwell S, Nishimura R, Weisbart R, Glazer P. Abstract 4319: Lupus antibody-based cancer therapy. Cancer Research 2013, 73: 4319-4319. DOI: 10.1158/1538-7445.am2013-4319.
  • Abstract 1513: MLH1 silencing is caused by hypoxia through epigenetic regulation..Lu Y, Wajapeyee N, Turker M, Glazer P. Abstract 1513: MLH1 silencing is caused by hypoxia through epigenetic regulation.. Cancer Research 2013, 73: 1513-1513. DOI: 10.1158/1538-7445.am2013-1513.
  • Genetic Instability Induced by Hypoxic StressScanlon S, Glazer P. Genetic Instability Induced by Hypoxic Stress 2013, 151-181. DOI: 10.1007/978-1-4614-6280-4_8.
  • A Rare Cell-penetrating Anti-DNA Antibody Inhibits DNA Repair, Sensitizes Tumors To DNA-damaging Therapy, and is Synthetically Lethal to BRCA2-deficient Cancer CellsHansen J, Chan G, Liu Y, Gera J, Sweasy J, Sung P, Rockwell S, Nishimura R, Weisbart R, Glazer P. A Rare Cell-penetrating Anti-DNA Antibody Inhibits DNA Repair, Sensitizes Tumors To DNA-damaging Therapy, and is Synthetically Lethal to BRCA2-deficient Cancer Cells International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s163. DOI: 10.1016/j.ijrobp.2012.07.422.
  • Vorinostat, a Histone Deacetylase Inhibitor, in Combination with Thoracic Radiotherapy in Advanced Non-small Cell Lung Cancer: A Dose Escalation StudyDecker R, Gettinger S, Glazer P, Wilson L. Vorinostat, a Histone Deacetylase Inhibitor, in Combination with Thoracic Radiotherapy in Advanced Non-small Cell Lung Cancer: A Dose Escalation Study International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s574-s575. DOI: 10.1016/j.ijrobp.2011.06.1074.
  • Preclinical Studies of Onrigen in Combination with RadiationRockwell S, Liu Y, Glazer P, Sartorelli A. Preclinical Studies of Onrigen in Combination with Radiation International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s752. DOI: 10.1016/j.ijrobp.2011.06.1249.
  • Abstract 3893: Mechanism of radiosensitization by inhibitors of poly(ADP-ribose) polymerase (PARP)Hegan D, Glazer P. Abstract 3893: Mechanism of radiosensitization by inhibitors of poly(ADP-ribose) polymerase (PARP) Cancer Research 2011, 71: 3893-3893. DOI: 10.1158/1538-7445.am2011-3893.
  • Abstract P6-04-04: Hypoxia Is Associated with Somatic Loss of BRCA1 Protein and Pathway Activity in Triple Negative Breast CancerNeumeister V, Li J, Lindner R, Sullivan C, Glazer P, Tuck D, Rimm D, Harris L. Abstract P6-04-04: Hypoxia Is Associated with Somatic Loss of BRCA1 Protein and Pathway Activity in Triple Negative Breast Cancer Cancer Research 2010, 70: p6-04-04-p6-04-04. DOI: 10.1158/0008-5472.sabcs10-p6-04-04.
  • Mechanism of Radiosensitization by Inhibitors of Poly (ADP-Ribose) Polymerase (PARP)Glazer P. Mechanism of Radiosensitization by Inhibitors of Poly (ADP-Ribose) Polymerase (PARP) International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s87-s88. DOI: 10.1016/j.ijrobp.2010.07.234.
  • Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL -deficient human renal cell carcinomaScanlon S, Hegan D, Sulkowski P, Glazer P. Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL -deficient human renal cell carcinoma Oncotarget 2010, 5: 2-2. DOI: 10.18632/oncotarget.23445.
  • Abstract 1969: Inhibition of poly(ADP-ribose) polymerase downregulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130Hegan D, Lu Y, Stachelek G, Crosby M, Bindra R, Glazer P. Abstract 1969: Inhibition of poly(ADP-ribose) polymerase downregulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130 Cancer Research 2010, 70: 1969-1969. DOI: 10.1158/1538-7445.am10-1969.
  • Abstract 2185: Identification of novel compounds that preferentially kill repair deficient cells using high-throughput screeningPeterson-Roth E, Abriola L, Merkel J, Glazer P. Abstract 2185: Identification of novel compounds that preferentially kill repair deficient cells using high-throughput screening Cancer Research 2010, 70: 2185-2185. DOI: 10.1158/1538-7445.am10-2185.
  • Abstract C21: Hypoxia-induced down-regulation of BRCA1 nuclear protein in human breast cancer tissuesLi J, Sullivan C, Numeister V, Rimm D, Glazer P, Harris L. Abstract C21: Hypoxia-induced down-regulation of BRCA1 nuclear protein in human breast cancer tissues Molecular Cancer Therapeutics 2009, 8: c21-c21. DOI: 10.1158/1535-7163.targ-09-c21.
  • Targeting Base Excision Repair to Potentiate Cancer TherapyGlazer P, Stachelek G, Dalal S, Sweasy J. Targeting Base Excision Repair to Potentiate Cancer Therapy International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s21. DOI: 10.1016/j.ijrobp.2009.07.071.
  • The Aberrant Expression of Beta-catenin in Esophageal Squamous Cell Cancer (ESCC) in Northeastern IranMani S, Moradi A, Abdolahi N, Martel M, Semnani S, Glazer P, Mani A. The Aberrant Expression of Beta-catenin in Esophageal Squamous Cell Cancer (ESCC) in Northeastern Iran International Journal Of Radiation Oncology • Biology • Physics 2007, 69: s309-s310. DOI: 10.1016/j.ijrobp.2007.07.1366.
  • Co-Repression of Mismatch Repair Gene Expression by Hypoxia in Cancer Cells: Role of the Myc/Max NetworkBindra R, Glazer P. Co-Repression of Mismatch Repair Gene Expression by Hypoxia in Cancer Cells: Role of the Myc/Max Network International Journal Of Radiation Oncology • Biology • Physics 2007, 69: s613. DOI: 10.1016/j.ijrobp.2007.07.1928.
  • 86 Complex Regulation of BRCA1 in Response to Hypoxic StressBindra R, Gibson S, Crosby M, Glazer P. 86 Complex Regulation of BRCA1 in Response to Hypoxic Stress International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s50. DOI: 10.1016/j.ijrobp.2006.07.116.
  • 708. Gene Targeting with Triplex-Forming Oligonucletides in the Pyrimidine MotifKalish J, Knauert M, Hegan D, Glazer P. 708. Gene Targeting with Triplex-Forming Oligonucletides in the Pyrimidine Motif Molecular Therapy 2006, 13: s273-s274. DOI: 10.1016/j.ymthe.2006.08.787.
  • 1031. Improved Intranuclear Delivery of PNA- Peptide Conjugates Designed for Chromosomal Gene TargetingRogers F, Glazer P. 1031. Improved Intranuclear Delivery of PNA- Peptide Conjugates Designed for Chromosomal Gene Targeting Molecular Therapy 2006, 13: s396. DOI: 10.1016/j.ymthe.2006.08.1126.
  • Peptide Nucleic Acids as Agents to Modify Target Gene Expression and FunctionWang G, Glazer P. Peptide Nucleic Acids as Agents to Modify Target Gene Expression and Function 2006, 223-235. DOI: 10.1007/0-387-32956-0_14.
  • 89. Gene Targeting of β_Globin IVS2 Using Sequence_Specific Peptide Nucleic AcidsKuan J, Kole R, Nielsen P, Glazer P. 89. Gene Targeting of β_Globin IVS2 Using Sequence_Specific Peptide Nucleic Acids Molecular Therapy 2006, 13: s37. DOI: 10.1016/j.ymthe.2006.08.107.
  • 1030. Pyrazolo[3,4-d]Pyrimidine Guanine Base Substitution in Triplex Forming Oligonucleotides Improves Target Specificity and Chromosomal MutagenesisChin J, Chin J, Lloyd J, Lloyd J, Rogers F, Glazer P. 1030. Pyrazolo[3,4-d]Pyrimidine Guanine Base Substitution in Triplex Forming Oligonucleotides Improves Target Specificity and Chromosomal Mutagenesis Molecular Therapy 2006, 13: s396. DOI: 10.1016/j.ymthe.2006.08.1125.
  • Dysregulation of BRCAL in HypoxiaGlazer P, Bindra R. Dysregulation of BRCAL in Hypoxia International Journal Of Radiation Oncology • Biology • Physics 2005, 63: s145. DOI: 10.1016/j.ijrobp.2005.07.247.
  • 67 Expression of DNA-dsb repair proteins is altered under hypoxia in prostate cancer cellsBristow R, Meng A, Jalali F, Hedley D, Nichol T, Sweet J, Milosevic M, Bindra R, Glazer P. 67 Expression of DNA-dsb repair proteins is altered under hypoxia in prostate cancer cells Radiotherapy And Oncology 2005, 76: s20-s21. DOI: 10.1016/s0167-8140(05)80228-2.
  • Targeted Gene Modification Using Triplex-Forming OligonucleotidesKuan J, Glazer P. Targeted Gene Modification Using Triplex-Forming Oligonucleotides 2004, 0: 173-194. DOI: 10.1385/1-59259-761-0:173.
  • Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cellsGlazer P, Bindra R, Schaffer P, Bristow R, Hedley D. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells International Journal Of Radiation Oncology • Biology • Physics 2004, 60: s193. DOI: 10.1016/j.ijrobp.2004.06.131.
  • Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cellsGLAZER P, BINDRA R, SCHAFFER P, BRISTOW R, HEDLEY D. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells International Journal Of Radiation Oncology • Biology • Physics 2004, 60: s193-s193. DOI: 10.1016/s0360-3016(04)01188-5.
  • Targeted Genome Modification Via Triple Helix FormationRogers F, Glazer P. Targeted Genome Modification Via Triple Helix Formation 2004, 27-43. DOI: 10.1007/978-1-59259-777-2_3.
  • Peptide nucleic acids as agents to modify target gene expression and functionWang G, Glazer P. Peptide nucleic acids as agents to modify target gene expression and function International Journal Of Peptide Research And Therapeutics 2003, 10: 335-345. DOI: 10.1007/s10989-004-4903-0.
  • Over-expression of the DNA mismatch repair factor, PMS2, confers ionizing radiation resistance and hypermutabilityGlazer P, Narayanan L, Liskay M, Campisi D. Over-expression of the DNA mismatch repair factor, PMS2, confers ionizing radiation resistance and hypermutability International Journal Of Radiation Oncology • Biology • Physics 2002, 54: 51-52. DOI: 10.1016/s0360-3016(02)03145-0.
  • Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombinationDatta H, Glazer P. Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination Nucleic Acids Research 2001, 29: 5140-5147. PMID: 11812847, PMCID: PMC97609, DOI: 10.1093/nar/29.24.5140.
  • ATM-dependent expression of the IGF-I receptor in a pathway regulating radiation responseGlazer P, Peretz S, Jensen R, Gibson S. ATM-dependent expression of the IGF-I receptor in a pathway regulating radiation response International Journal Of Radiation Oncology • Biology • Physics 2001, 51: 55. DOI: 10.1016/s0360-3016(01)01923-x.
  • Triplex forming oligonucleotides: sequence-specific tools for gene targetingKnauert M, Glazer P. Triplex forming oligonucleotides: sequence-specific tools for gene targeting Human Molecular Genetics 2001, 10: 2243-2251. PMID: 11673407, DOI: 10.1093/hmg/10.20.2243.
  • Chromosome Targeting at Short Polypurine Sites by Cationic Triplex-forming Oligonucleotides*Vasquez K, Dagle J, Weeks D, Glazer P. Chromosome Targeting at Short Polypurine Sites by Cationic Triplex-forming Oligonucleotides* Journal Of Biological Chemistry 2001, 276: 38536-38541. PMID: 11504712, DOI: 10.1074/jbc.m101797200.
  • Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice.Xu X, Narayanan L, Dunklee B, Liskay R, Glazer P. Hypermutability to ionizing radiation in mismatch repair-deficient, Pms2 knockout mice. Cancer Research 2001, 61: 3775-80. PMID: 11325851.
  • Triplex-induced Recombination in Human Cell-free Extracts DEPENDENCE ON XPA AND HsRad51*Datta H, Chan P, Vasquez K, Gupta R, Glazer P. Triplex-induced Recombination in Human Cell-free Extracts DEPENDENCE ON XPA AND HsRad51* Journal Of Biological Chemistry 2001, 276: 18018-18023. PMID: 11278954, DOI: 10.1074/jbc.m011646200.
  • ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation responsePeretz S, Jensen R, Baserga R, Glazer P. ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response Proceedings Of The National Academy Of Sciences Of The United States Of America 2001, 98: 1676-1681. PMID: 11172010, PMCID: PMC29316, DOI: 10.1073/pnas.98.4.1676.
  • Genomic Instability in CancerRockwell S, Yuan J, Peretz S, Glazer P. Genomic Instability in Cancer 2001, 240: 133-151. PMID: 11727926, DOI: 10.1002/0470868716.ch9.
  • Gene targeting via triple-helix formationCasey B, Glazer P. Gene targeting via triple-helix formation 2001, 67: 163-192. PMID: 11525382, DOI: 10.1016/s0079-6603(01)67028-4.
  • Specific Mutations Induced by Triplex-Forming Oligonucleotides in MiceVasquez K, Narayanan L, Glazer P. Specific Mutations Induced by Triplex-Forming Oligonucleotides in Mice Science 2000, 290: 530-533. PMID: 11039937, DOI: 10.1126/science.290.5491.530.
  • Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways.Zeng M, Narayanan L, Xu X, Prolla T, Liskay R, Glazer P. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways. Cancer Research 2000, 60: 4889-93. PMID: 10987303.
  • High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cellsLuo Z, Macris M, Faruqi A, Glazer P. High-frequency intrachromosomal gene conversion induced by triplex-forming oligonucleotides microinjected into mouse cells Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 9003-9008. PMID: 10900269, PMCID: PMC16811, DOI: 10.1073/pnas.160004997.
  • Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiationTurner B, Gumbs A, Carter D, Glazer P, Haffty B. Cyclin D1 expression and early breast cancer recurrence following lumpectomy and radiation International Journal Of Radiation Oncology • Biology • Physics 2000, 47: 1169-1176. PMID: 10889369, DOI: 10.1016/s0360-3016(00)00525-3.
  • Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshiftsAndrew S, Xu X, Baross-Francis A, Narayanan L, Milhausen K, Liskay R, Jirik F, Glazer P. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts Carcinogenesis 2000, 21: 1291-1296. PMID: 10874005, DOI: 10.1093/carcin/21.7.1291.
  • Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshiftsAndrew S, Xu X, Baross-Francis A, Narayanan L, Milhausen K, Liskay R, Jirik F, Glazer P. Mutagenesis in PMS2- and MSH2-deficient mice indicates differential protection from transversions and frameshifts Carcinogenesis 2000, 21: 1291-1296. DOI: 10.1093/carcin/21.5.291.
  • Better than the real thing: peptide nucleic acids Peptide Nucleic Acids: Protocols and Applications edited by Peter E. Nielsen and Michael EgholmGlazer P. Better than the real thing: peptide nucleic acids Peptide Nucleic Acids: Protocols and Applications edited by Peter E. Nielsen and Michael Egholm Trends In Genetics 2000, 16: 278. DOI: 10.1016/s0168-9525(00)01994-6.
  • Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapyTurner B, Gumbs A, Carbone C, Carter D, Glazer P, Haffty B. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy Cancer 2000, 88: 1091-1098. PMID: 10699900, DOI: 10.1002/(sici)1097-0142(20000301)88:5<1091::aid-cncr21>3.0.co;2-y.
  • Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiationYoo S, Carter D, Turner B, Sasaki C, Son Y, Wilson L, Glazer P, Haffty B. Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation International Journal Of Cancer 2000, 90: 22-28. PMID: 10725854, DOI: 10.1002/(sici)1097-0215(20000220)90:1<22::aid-ijc3>3.0.co;2-t.
  • Triple-Helix Formation Induces Recombination in Mammalian Cells via a Nucleotide Excision Repair-Dependent PathwayFaruqi A, Datta H, Carroll D, Seidman M, Glazer P. Triple-Helix Formation Induces Recombination in Mammalian Cells via a Nucleotide Excision Repair-Dependent Pathway Molecular And Cellular Biology 2000, 20: 990-1000. PMID: 10629056, PMCID: PMC85216, DOI: 10.1128/mcb.20.3.990-1000.2000.
  • DNA Repair Protocols: Eukaryotic SystemsGlazer P. DNA Repair Protocols: Eukaryotic Systems Radiation Research 2000, 153: 241-242. DOI: 10.1667/0033-7587(2000)153[0241:drpes]2.0.co;2.
  • Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pHGlazer P, Yuan J, Rockwell S, Narayanan L. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 288. DOI: 10.1016/s0360-3016(00)80378-8.
  • Activation of human γ-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ-globin gene 5′ flanking regionXu X, Glazer P, Wang G. Activation of human γ-globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ-globin gene 5′ flanking region Gene 2000, 242: 219-228. PMID: 10721715, DOI: 10.1016/s0378-1119(99)00522-3.
  • The influence of the DNA mismatch repair gene, Pms2, on the celluar response to ionizing radiation at low dose ratesZeng M, Narayanan L, Glazer P. The influence of the DNA mismatch repair gene, Pms2, on the celluar response to ionizing radiation at low dose rates International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 287. DOI: 10.1016/s0360-3016(00)80376-4.
  • BRCA1/BRCA2 in breast-conserving therapy.Turner B, Glazer P, Haffty B. BRCA1/BRCA2 in breast-conserving therapy. Journal Of Clinical Oncology 1999, 17: 3689. PMID: 10550169.
  • BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations.Turner B, Harrold E, Matloff E, Smith T, Gumbs A, Beinfield M, Ward B, Skolnick M, Glazer P, Thomas A, Haffty B. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. Journal Of Clinical Oncology 1999, 17: 3017-24. PMID: 10506595, DOI: 10.1200/jco.1999.17.10.3017.
  • The Tyr-265-to-Cys mutator mutant of DNA polymerase β induces a mutator phenotype in mouse LN12 cellsClairmont C, Narayanan L, Sun K, Glazer P, Sweasy J. The Tyr-265-to-Cys mutator mutant of DNA polymerase β induces a mutator phenotype in mouse LN12 cells Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 9580-9585. PMID: 10449735, PMCID: PMC22251, DOI: 10.1073/pnas.96.17.9580.
  • Peptide nucleic acid (PNA) binding-mediated induction of human γ-globin gene expressionWang G, Xu X, Pace B, Dean D, Glazer P, Chan P, Goodman S, Shokolenko I. Peptide nucleic acid (PNA) binding-mediated induction of human γ-globin gene expression Nucleic Acids Research 1999, 27: 2806-2813. PMID: 10373600, PMCID: PMC148492, DOI: 10.1093/nar/27.13.2806.
  • Different mutator phenotypes in Mlh1- versus Pms2-deficient miceYao X, Buermeyer A, Narayanan L, Tran D, Baker S, Prolla T, Glazer P, Liskay R, Arnheim N. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 6850-6855. PMID: 10359802, PMCID: PMC22005, DOI: 10.1073/pnas.96.12.6850.
  • Targeted Correction of an Episomal Gene in Mammalian Cells by a Short DNA Fragment Tethered to a Triplex-forming Oligonucleotide*Chan P, Lin M, Faruqi A, Powell J, Seidman M, Glazer P. Targeted Correction of an Episomal Gene in Mammalian Cells by a Short DNA Fragment Tethered to a Triplex-forming Oligonucleotide* Journal Of Biological Chemistry 1999, 274: 11541-11548. PMID: 10206960, DOI: 10.1074/jbc.274.17.11541.
  • Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cellsVasquez K, Wang G, Havre P, Glazer P. Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells Nucleic Acids Research 1999, 27: 1176-1181. PMID: 9927753, PMCID: PMC148300, DOI: 10.1093/nar/27.4.1176.
  • Triplex Formation by Oligonucleotides Containing 5-(1-Propynyl)-2‘-deoxyuridine: Decreased Magnesium Dependence and Improved Intracellular Gene Targeting †Lacroix L, Lacoste J, Reddoch J, Mergny J, Levy D, Seidman M, Matteucci M, Glazer P. Triplex Formation by Oligonucleotides Containing 5-(1-Propynyl)-2‘-deoxyuridine: Decreased Magnesium Dependence and Improved Intracellular Gene Targeting † Biochemistry 1999, 38: 1893-1901. PMID: 10026270, DOI: 10.1021/bi982290q.
  • 93 The germline p53 13964 gc mutation confers resistance to radiation in familial breast cancer patientsTurner B, Lehman T, Modali R, Carbone C, Bishop L, Curran W, Glazer P, Haffty B. 93 The germline p53 13964 gc mutation confers resistance to radiation in familial breast cancer patients International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 195. DOI: 10.1016/s0360-3016(99)90111-6.
  • 156 Cyclin D1 expression mediates sensitivity in ataxia telangiectasia and breast cancerFritzell J, Glazer P, Haffty B, Gumbs A, Wang L, Carter D, Musgrove E, Curran W, Sutherland R, Turner B. 156 Cyclin D1 expression mediates sensitivity in ataxia telangiectasia and breast cancer International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 228. DOI: 10.1016/s0360-3016(99)90174-8.
  • 105 Tumor hypoxia induces and selects for overexpression of the igf-i receptor: Implications for tumor progression and radioresistancePeretz S, Kim C, Rockwell S, Baserga R, Glazer P. 105 Tumor hypoxia induces and selects for overexpression of the igf-i receptor: Implications for tumor progression and radioresistance International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 201. DOI: 10.1016/s0360-3016(99)90123-2.
  • Genome Modification by Triplex-Forming OligonucleotidesVasquez K, Glazer P. Genome Modification by Triplex-Forming Oligonucleotides 1999, 2: 167-179. DOI: 10.1007/978-1-4615-5177-5_13.
  • 154 Role of DNA mismatch repair in the cell response to ionizing radiationZeng M, Narayanan L, Xu S, Liskay M, Glazer P. 154 Role of DNA mismatch repair in the cell response to ionizing radiation International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 227. DOI: 10.1016/s0360-3016(99)90172-4.
  • Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways.Turner B, Zhang J, Gumbs A, Maher M, Kaplan L, Carter D, Glazer P, Hurst H, Haffty B, Williams T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Research 1998, 58: 5466-72. PMID: 9850080.
  • Targeted gene knockout mediated by triple helix forming oligonucleotidesMajumdar A, Khorlin A, Dyatkina N, Lin F, Powell J, Liu J, Fei Z, Khripine Y, Watanabe K, George J, Glazer P, Seidman M. Targeted gene knockout mediated by triple helix forming oligonucleotides Nature Genetics 1998, 20: 212-214. PMID: 9771719, DOI: 10.1038/2530.
  • Mutagenesis induced by the tumor microenvironmentYuan J, Glazer P. Mutagenesis induced by the tumor microenvironment Mutation Research/Fundamental And Molecular Mechanisms Of Mutagenesis 1998, 400: 439-446. PMID: 9685702, DOI: 10.1016/s0027-5107(98)00042-6.
  • Mutagenesis Mediated by Triple Helix–Forming Oligonucleotides Conjugated to Psoralen: Effects of Linker Arm Length and Sequence ContextRaha M, Lacroix L, Glazer P. Mutagenesis Mediated by Triple Helix–Forming Oligonucleotides Conjugated to Psoralen: Effects of Linker Arm Length and Sequence Context Photochemistry And Photobiology 1998, 67: 289-294. PMID: 9523530, DOI: 10.1111/j.1751-1097.1998.tb05201.x.
  • Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cellsFaruqi A, Egholm M, Glazer P. Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 1398-1403. PMID: 9465026, PMCID: PMC19018, DOI: 10.1073/pnas.95.4.1398.
  • Elevated frequency of germline BRCA1/BRCA2 gene mutations in locally recurrent breast cancer patients following lumpectomy and radiation therapy: Implications for breast conserving management in affected patientsTurner B, Harrold E, Gumbs A, Matloff E, Ward B, Thomas A, Glazer P, Haffty B. Elevated frequency of germline BRCA1/BRCA2 gene mutations in locally recurrent breast cancer patients following lumpectomy and radiation therapy: Implications for breast conserving management in affected patients International Journal Of Radiation Oncology • Biology • Physics 1998, 42: 179. DOI: 10.1016/s0360-3016(98)80210-1.
  • Role of DNA mismatch repair in response to ionizing radiationGlazer P, Fritzell J, Narayanan L. Role of DNA mismatch repair in response to ionizing radiation International Journal Of Radiation Oncology • Biology • Physics 1998, 42: 154. DOI: 10.1016/s0360-3016(98)80160-0.
  • Role of DNA mismatch repair in the cytotoxicity of ionizing radiation.Fritzell J, Narayanan L, Baker S, Bronner C, Andrew S, Prolla T, Bradley A, Jirik F, Liskay R, Glazer P. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Research 1997, 57: 5143-7. PMID: 9371516.
  • Processing of targeted psoralen cross-links in Xenopus oocytes.Segal D, Faruqi A, Glazer P, Carroll D. Processing of targeted psoralen cross-links in Xenopus oocytes. Molecular And Cellular Biology 1997, 17: 6645-6652. PMID: 9343428, PMCID: PMC232518, DOI: 10.1128/mcb.17.11.6645.
  • Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2Narayanan L, Fritzell J, Baker S, Liskay R, Glazer P. Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene Pms2 Proceedings Of The National Academy Of Sciences Of The United States Of America 1997, 94: 3122-3127. PMID: 9096356, PMCID: PMC20332, DOI: 10.1073/pnas.94.7.3122.
  • Triplex DNA: fundamentals, advances, and potential applications for gene therapyChan P, Glazer P. Triplex DNA: fundamentals, advances, and potential applications for gene therapy Journal Of Molecular Medicine 1997, 75: 267-282. PMID: 9151213, DOI: 10.1007/s001090050112.
  • Potassium-Resistant Triple Helix Formation and Improved Intracellular Gene Targeting by Oligodeoxyribonucleotides Containing 7-DeazaxanthineFaruqi A, Krawczyk S, Matteucci M, Glazer P. Potassium-Resistant Triple Helix Formation and Improved Intracellular Gene Targeting by Oligodeoxyribonucleotides Containing 7-Deazaxanthine Nucleic Acids Research 1997, 25: 633-640. PMID: 9016606, PMCID: PMC146453, DOI: 10.1093/nar/25.3.633.
  • 1 The regulation of ipsilateral breast tumor recurrence after lumpectomy and radiation therapy by the transcription factors p53 and AP2Turner B, Glazer P, Gumbs A, Kaplan L, Maher M, Hurst H, Carter D, Williams T, Haffty B. 1 The regulation of ipsilateral breast tumor recurrence after lumpectomy and radiation therapy by the transcription factors p53 and AP2 International Journal Of Radiation Oncology • Biology • Physics 1997, 39: 135. DOI: 10.1016/s0360-3016(97)80558-5.
  • Facilitating oligonucleotide delivery: helping antisense deliver on its promise.Gewirtz A, Stein C, Glazer P. Facilitating oligonucleotide delivery: helping antisense deliver on its promise. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 3161-3163. PMID: 8622906, PMCID: PMC39574, DOI: 10.1073/pnas.93.8.3161.
  • Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant.Raha M, Wang G, Seidman M, Glazer P. Mutagenesis by third-strand-directed psoralen adducts in repair-deficient human cells: high frequency and altered spectrum in a xeroderma pigmentosum variant. Proceedings Of The National Academy Of Sciences Of The United States Of America 1996, 93: 2941-2946. PMID: 8610147, PMCID: PMC39739, DOI: 10.1073/pnas.93.7.2941.
  • RecA protein-mediated irreversible fixation of an oligodeoxyribonucleotide to specific site in DNAGolub E, Glazer P, Ward D, Radding C. RecA protein-mediated irreversible fixation of an oligodeoxyribonucleotide to specific site in DNA Mutation Research/Fundamental And Molecular Mechanisms Of Mutagenesis 1996, 351: 117-124. PMID: 8622705, DOI: 10.1016/0027-5107(95)00212-x.
  • Mutagenesis in Mammalian Cells Induced by Triple Helix Formation and Transcription-Coupled RepairWang G, Seidman M, Glazer P. Mutagenesis in Mammalian Cells Induced by Triple Helix Formation and Transcription-Coupled Repair Science 1996, 271: 802-805. PMID: 8628995, DOI: 10.1126/science.271.5250.802.
  • Triplex‐Mediated, in vitro Targeting of Psoralen Photoadducts within the Genome of a Transgenic MouseGunther E, Havre P, Gasparro F, Glazer P. Triplex‐Mediated, in vitro Targeting of Psoralen Photoadducts within the Genome of a Transgenic Mouse Photochemistry And Photobiology 1996, 63: 207-212. PMID: 8657733, DOI: 10.1111/j.1751-1097.1996.tb03015.x.
  • Targeted Mutagenesis Mediated by the Triple Helix FormationGlazer P, Wang G, Havre P, Gunther E. Targeted Mutagenesis Mediated by the Triple Helix Formation 1996, 57: 109-118. DOI: 10.1385/0-89603-332-5:109.
  • Targeted Mutagenesis Mediated by the Triple Helix FormationGlazer P, Wang G, Havre P, Gunther E. Targeted Mutagenesis Mediated by the Triple Helix Formation 1996, 57: 109-118. PMID: 8849999, DOI: 10.1385/0-89603-332-5:109.
  • 41 Insulin growth factor-1 receptor (IGF-1R) expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control studyTurner B, Haffty B, Carter D, Gumbs A, Naryanan L, Baserga R, Glazer P. 41 Insulin growth factor-1 receptor (IGF-1R) expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 179. DOI: 10.1016/s0360-3016(97)85382-5.
  • Other transgenic mutation assays: Tissue specificity of spontaneous point mutations in λsupF transgenic miceLeach E, Narayanan L, Havre P, Gunther E, Yeasky T, Glazer P. Other transgenic mutation assays: Tissue specificity of spontaneous point mutations in λsupF transgenic mice Environmental And Molecular Mutagenesis 1996, 28: 459-464. PMID: 8991078, DOI: 10.1002/(sici)1098-2280(1996)28:4<459::aid-em23>3.0.co;2-d.
  • Frequent spontaneous deletions at a shuttle vector locus in transgenic miceLeach E, Gunther E, Yeasky T, Gibson L, Yang-Feng T, Glazer P. Frequent spontaneous deletions at a shuttle vector locus in transgenic mice Mutagenesis 1996, 11: 49-56. PMID: 8671715, DOI: 10.1093/mutage/11.1.49.
  • p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells.Havre P, Yuan J, Hedrick L, Cho K, Glazer P. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Research 1995, 55: 4420-4. PMID: 7671255.
  • Altered Repair of Targeted Psoralen Photoadducts in the Context of an Oligonucleotide-mediated Triple Helix (∗)Wang G, Glazer P. Altered Repair of Targeted Psoralen Photoadducts in the Context of an Oligonucleotide-mediated Triple Helix (∗) Journal Of Biological Chemistry 1995, 270: 22595-22601. PMID: 7673252, DOI: 10.1074/jbc.270.38.22595.
  • Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by offoadducts as well as cross-links.Gunther E, Yeasky T, Gasparro F, Glazer P. Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by offoadducts as well as cross-links. Cancer Research 1995, 55: 1283-8. PMID: 7882323.
  • Frequent T:A-->G:C transversions in X-irradiated mouse cells.Yuan J, Yeasky T, Rhee M, Glazer P. Frequent T:A-->G:C transversions in X-irradiated mouse cells. Carcinogenesis 1995, 16: 83-8. PMID: 7834808, DOI: 10.1093/carcin/16.1.83.
  • Induction of p53 in mouse cells decreases mutagenesis by UV radiation.Yuan J, Yeasky T, Havre P, Glazer P. Induction of p53 in mouse cells decreases mutagenesis by UV radiation. Carcinogenesis 1995, 16: 2295-300. PMID: 7586125, DOI: 10.1093/carcin/16.10.2295.
  • Distinctive spectrum of point mutations in x-ray treated mouse cells: Implications for DNA damage and repair pathwaysGlazer P, Yuan J, Yeasky T, Rhee M. Distinctive spectrum of point mutations in x-ray treated mouse cells: Implications for DNA damage and repair pathways International Journal Of Radiation Oncology • Biology • Physics 1994, 30: 237-238. DOI: 10.1016/0360-3016(94)90771-4.
  • Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formationGasparro F, Havre P, Olack G, Gunther E, Glazer P. Site-specific targeting of psoralen photoadducts with a triple helix-forming oligonucleotide: characterization of psoralen monoadduct and crosslink formation Nucleic Acids Research 1994, 22: 2845-2852. PMID: 8052539, PMCID: PMC308256, DOI: 10.1093/nar/22.14.2845.
  • Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide.Havre P, Glazer P. Targeted mutagenesis of simian virus 40 DNA mediated by a triple helix-forming oligonucleotide. Journal Of Virology 1993, 67: 7324-31. PMID: 8230456, PMCID: PMC238196, DOI: 10.1128/jvi.67.12.7324-7331.1993.
  • High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage lambda DNA using a new E.coli lysogenGunther E, Murray N, Glazer P. High efficiency, restriction-deficient in vitro packaging extracts for bacteriophage lambda DNA using a new E.coli lysogen Nucleic Acids Research 1993, 21: 3903-3904. PMID: 8396240, PMCID: PMC309930, DOI: 10.1093/nar/21.16.3903.
  • Lambda phage shuttle vectors for analysis of mutations in mammalian cells in culture and in transgenic miceSummers W, Glazer P, Malkevich D. Lambda phage shuttle vectors for analysis of mutations in mammalian cells in culture and in transgenic mice Mutation Research/Fundamental And Molecular Mechanisms Of Mutagenesis 1989, 220: 263-268. PMID: 2522589, DOI: 10.1016/0165-1110(89)90030-4.
  • UV-induced DNA-binding proteins in human cells.Glazer P, Greggio N, Metherall J, Summers W. UV-induced DNA-binding proteins in human cells. Proceedings Of The National Academy Of Sciences Of The United States Of America 1989, 86: 1163-1167. PMID: 2919165, PMCID: PMC286646, DOI: 10.1073/pnas.86.4.1163.
  • Mismatch Repair in Mammalian Cells: Approaches to the in Vitro Study of DNA Mismatch Correction ReactionsSummers W, Glazer P. Mismatch Repair in Mammalian Cells: Approaches to the in Vitro Study of DNA Mismatch Correction Reactions 1989, 255-261. DOI: 10.1007/978-1-4684-1327-4_24.
  • Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line.Lacy J, Summers W, Watson M, Glazer P, Summers W. Amplification and deregulation of MYC following Epstein-Barr virus infection of a human B-cell line. Proceedings Of The National Academy Of Sciences Of The United States Of America 1987, 84: 5838-5842. PMID: 3039510, PMCID: PMC298958, DOI: 10.1073/pnas.84.16.5838.
  • DNA mismatch repair detected in human cell extracts.Glazer P, Sarkar S, Chisholm G, Summers W. DNA mismatch repair detected in human cell extracts. Molecular And Cellular Biology 1987, 7: 218-224. PMID: 3031461, PMCID: PMC365059, DOI: 10.1128/mcb.7.1.218.
  • DNA mismatch repair detected in human cell extractsGlazer P, Sarkar S, Chisholm G, Summers W. DNA mismatch repair detected in human cell extracts Molecular And Cellular Biology 1987, 7: 218-224. DOI: 10.1128/mcb.7.1.218-224.1987.
  • Detection and analysis of UV-induced mutations in mammalian cell DNA using a lambda phage shuttle vector.Glazer P, Sarkar S, Summers W. Detection and analysis of UV-induced mutations in mammalian cell DNA using a lambda phage shuttle vector. Proceedings Of The National Academy Of Sciences Of The United States Of America 1986, 83: 1041-1044. PMID: 2937054, PMCID: PMC323006, DOI: 10.1073/pnas.83.4.1041.
  • Oncogene Expression in Isogenic, EBV-Positive and -Negative Burkitt Lymphoma Cell LinesGlazer P, Summers W. Oncogene Expression in Isogenic, EBV-Positive and -Negative Burkitt Lymphoma Cell Lines Intervirology 1985, 23: 82-89. PMID: 2984143, DOI: 10.1159/000149589.
  • Direct and inducible mutagenesis in mammalian cells.Summers W, Sarkar S, Glazer P. Direct and inducible mutagenesis in mammalian cells. Cancer Surveys 1985, 4: 517-28. PMID: 3916654.
Edit Profile